http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
-
Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting
-
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
-
Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting
-
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
-
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
-
Zynerba Pharma (ZYNE) Presents Data on Zygel
-
Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference
-
Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference
-
Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference
-
Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference
-
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank
-
Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank
-
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
-
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
-
Zynerba Pharma (ZYNE) Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
-
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
-
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
-
Zynerba Pharma (ZYNE) Pushes Results Target for Phase 3 Trial of Zygel to H1 2024
-
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
-
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
-
Zynerba Pharma (ZYNE) Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
-
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
-
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
-
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
-
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
-
Zynerba Pharma (ZYNE) Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel in the Journal of Neurodevelopmental Disorders
-
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
-
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
-
Zynerba Pharma (ZYNE) Announces European Commission Has Granted Orphan Drug Designation for Zygel in 22q11.2 Deletion Syndrome
-
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
-
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
-
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharma (ZYNE) Receives New U.S. Patent for Zygel
-
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
-
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
-
Zynerba Pharma (ZYNE) Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion
-
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthr
-
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthr
-
Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
-
Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
-
Zynerba Pharma (ZYNE) Announces Issuance of New U.S. Patent for Zygel
-
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
-
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
-
Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
